Mealey's PI/Product Liability - FDA Study Finds Lower Risk Of Stroke, Death From Pradaxa, But Higher GI Bleed Risk

Mealey's PI/Product Liability - FDA Study Finds Lower Risk Of Stroke, Death From Pradaxa, But Higher GI Bleed Risk

SILVER SPRING, Md. - The Food and Drug Administration on May 13 said a recently completed study of Pradaxa found that the new anticoagulant has a lower risk of stroke and death compared to warfarin but has a higher risk for major gastrointestinal (GI) bleeding compared to warfarin, an established drug in the same class.

Find full version on lexis Advance®
Access this news story on lexis.com®